The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Venous Thromboembolism Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
The global Venous Thromboembolism Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Venous Thromboembolism Therapeutics in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Other, are propelling Venous Thromboembolism Therapeutics market. Factor Xa Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Direct Thrombin Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Venous Thromboembolism Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Venous Thromboembolism Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Venous Thromboembolism Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Venous Thromboembolism Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Venous Thromboembolism Therapeutics covered in this report include Johnson & Johnson, Sanofi, Boehringer Ingelheim, Daiichi Sankyo, Bristol-Myers Squibb (BMS), Bayer HealthCare, Pfizer, Leo Pharma and Portola Pharmaceuticals, etc.
The global Venous Thromboembolism Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Johnson & Johnson
Sanofi
Boehringer Ingelheim
Daiichi Sankyo
Bristol-Myers Squibb (BMS)
Bayer HealthCare
Pfizer
Leo Pharma
Portola Pharmaceuticals
ThromboGenics
Ionis Pharmaceuticals
GlycoMimetics
BioInvent International
Global Venous Thromboembolism Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Venous Thromboembolism Therapeutics market, Segment by Type:
Factor Xa Inhibitors
Direct Thrombin Inhibitors
Heparin
Vitamin K Antagonists
Other
Global Venous Thromboembolism Therapeutics market, by Application
Hospital Pharmacies
Retail Pharmacies
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Venous Thromboembolism Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Venous Thromboembolism Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Venous Thromboembolism Therapeutics in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Other, are propelling Venous Thromboembolism Therapeutics market. Factor Xa Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Direct Thrombin Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Venous Thromboembolism Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Venous Thromboembolism Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Venous Thromboembolism Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Venous Thromboembolism Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Venous Thromboembolism Therapeutics covered in this report include Johnson & Johnson, Sanofi, Boehringer Ingelheim, Daiichi Sankyo, Bristol-Myers Squibb (BMS), Bayer HealthCare, Pfizer, Leo Pharma and Portola Pharmaceuticals, etc.
The global Venous Thromboembolism Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Johnson & Johnson
Sanofi
Boehringer Ingelheim
Daiichi Sankyo
Bristol-Myers Squibb (BMS)
Bayer HealthCare
Pfizer
Leo Pharma
Portola Pharmaceuticals
ThromboGenics
Ionis Pharmaceuticals
GlycoMimetics
BioInvent International
Global Venous Thromboembolism Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Venous Thromboembolism Therapeutics market, Segment by Type:
Factor Xa Inhibitors
Direct Thrombin Inhibitors
Heparin
Vitamin K Antagonists
Other
Global Venous Thromboembolism Therapeutics market, by Application
Hospital Pharmacies
Retail Pharmacies
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Venous Thromboembolism Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Venous Thromboembolism Therapeutics
1.1 Venous Thromboembolism Therapeutics Market Overview
1.1.1 Venous Thromboembolism Therapeutics Product Scope
1.1.2 Venous Thromboembolism Therapeutics Market Status and Outlook
1.2 Global Venous Thromboembolism Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Venous Thromboembolism Therapeutics Market Size by Region (2018-2029)
1.4 Global Venous Thromboembolism Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Venous Thromboembolism Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Venous Thromboembolism Therapeutics Market Size (2018-2029)
1.6.1 North America Venous Thromboembolism Therapeutics Market Size (2018-2029)
1.6.2 Europe Venous Thromboembolism Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Venous Thromboembolism Therapeutics Market Size (2018-2029)
1.6.4 Latin America Venous Thromboembolism Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Venous Thromboembolism Therapeutics Market Size (2018-2029)
2 Venous Thromboembolism Therapeutics Market by Type
2.1 Introduction
2.1.1 Factor Xa Inhibitors
2.1.2 Direct Thrombin Inhibitors
2.1.3 Heparin
2.1.4 Vitamin K Antagonists
2.1.5 Other
2.2 Global Venous Thromboembolism Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Venous Thromboembolism Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Venous Thromboembolism Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Venous Thromboembolism Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Venous Thromboembolism Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Venous Thromboembolism Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Venous Thromboembolism Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Venous Thromboembolism Therapeutics Revenue Breakdown by Type (2018-2029)
3 Venous Thromboembolism Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Other
3.2 Global Venous Thromboembolism Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Venous Thromboembolism Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Venous Thromboembolism Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Venous Thromboembolism Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Venous Thromboembolism Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Venous Thromboembolism Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Venous Thromboembolism Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Venous Thromboembolism Therapeutics Revenue Breakdown by Application (2018-2029)
4 Venous Thromboembolism Therapeutics Competition Analysis by Players
4.1 Global Venous Thromboembolism Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Venous Thromboembolism Therapeutics as of 2022)
4.3 Date of Key Players Enter into Venous Thromboembolism Therapeutics Market
4.4 Global Top Players Venous Thromboembolism Therapeutics Headquarters and Area Served
4.5 Key Players Venous Thromboembolism Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Venous Thromboembolism Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Johnson & Johnson
5.1.1 Johnson & Johnson Profile
5.1.2 Johnson & Johnson Main Business
5.1.3 Johnson & Johnson Venous Thromboembolism Therapeutics Products, Services and Solutions
5.1.4 Johnson & Johnson Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Johnson & Johnson Recent Developments
5.2 Sanofi
5.2.1 Sanofi Profile
5.2.2 Sanofi Main Business
5.2.3 Sanofi Venous Thromboembolism Therapeutics Products, Services and Solutions
5.2.4 Sanofi Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Sanofi Recent Developments
5.3 Boehringer Ingelheim
5.3.1 Boehringer Ingelheim Profile
5.3.2 Boehringer Ingelheim Main Business
5.3.3 Boehringer Ingelheim Venous Thromboembolism Therapeutics Products, Services and Solutions
5.3.4 Boehringer Ingelheim Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Daiichi Sankyo Recent Developments
5.4 Daiichi Sankyo
5.4.1 Daiichi Sankyo Profile
5.4.2 Daiichi Sankyo Main Business
5.4.3 Daiichi Sankyo Venous Thromboembolism Therapeutics Products, Services and Solutions
5.4.4 Daiichi Sankyo Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Daiichi Sankyo Recent Developments
5.5 Bristol-Myers Squibb (BMS)
5.5.1 Bristol-Myers Squibb (BMS) Profile
5.5.2 Bristol-Myers Squibb (BMS) Main Business
5.5.3 Bristol-Myers Squibb (BMS) Venous Thromboembolism Therapeutics Products, Services and Solutions
5.5.4 Bristol-Myers Squibb (BMS) Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Bristol-Myers Squibb (BMS) Recent Developments
5.6 Bayer HealthCare
5.6.1 Bayer HealthCare Profile
5.6.2 Bayer HealthCare Main Business
5.6.3 Bayer HealthCare Venous Thromboembolism Therapeutics Products, Services and Solutions
5.6.4 Bayer HealthCare Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Bayer HealthCare Recent Developments
5.7 Pfizer
5.7.1 Pfizer Profile
5.7.2 Pfizer Main Business
5.7.3 Pfizer Venous Thromboembolism Therapeutics Products, Services and Solutions
5.7.4 Pfizer Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Pfizer Recent Developments
5.8 Leo Pharma
5.8.1 Leo Pharma Profile
5.8.2 Leo Pharma Main Business
5.8.3 Leo Pharma Venous Thromboembolism Therapeutics Products, Services and Solutions
5.8.4 Leo Pharma Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Leo Pharma Recent Developments
5.9 Portola Pharmaceuticals
5.9.1 Portola Pharmaceuticals Profile
5.9.2 Portola Pharmaceuticals Main Business
5.9.3 Portola Pharmaceuticals Venous Thromboembolism Therapeutics Products, Services and Solutions
5.9.4 Portola Pharmaceuticals Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Portola Pharmaceuticals Recent Developments
5.10 ThromboGenics
5.10.1 ThromboGenics Profile
5.10.2 ThromboGenics Main Business
5.10.3 ThromboGenics Venous Thromboembolism Therapeutics Products, Services and Solutions
5.10.4 ThromboGenics Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 ThromboGenics Recent Developments
5.11 Ionis Pharmaceuticals
5.11.1 Ionis Pharmaceuticals Profile
5.11.2 Ionis Pharmaceuticals Main Business
5.11.3 Ionis Pharmaceuticals Venous Thromboembolism Therapeutics Products, Services and Solutions
5.11.4 Ionis Pharmaceuticals Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Ionis Pharmaceuticals Recent Developments
5.12 GlycoMimetics
5.12.1 GlycoMimetics Profile
5.12.2 GlycoMimetics Main Business
5.12.3 GlycoMimetics Venous Thromboembolism Therapeutics Products, Services and Solutions
5.12.4 GlycoMimetics Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 GlycoMimetics Recent Developments
5.13 BioInvent International
5.13.1 BioInvent International Profile
5.13.2 BioInvent International Main Business
5.13.3 BioInvent International Venous Thromboembolism Therapeutics Products, Services and Solutions
5.13.4 BioInvent International Venous Thromboembolism Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 BioInvent International Recent Developments
6 North America
6.1 North America Venous Thromboembolism Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Venous Thromboembolism Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Venous Thromboembolism Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Venous Thromboembolism Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Venous Thromboembolism Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Venous Thromboembolism Therapeutics Market Dynamics
11.1 Venous Thromboembolism Therapeutics Industry Trends
11.2 Venous Thromboembolism Therapeutics Market Drivers
11.3 Venous Thromboembolism Therapeutics Market Challenges
11.4 Venous Thromboembolism Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
